Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')
Clinical trial NCT04946227 · UNKNOWN
Trial details
- NCT number
- NCT04946227
- Sponsor
- Yonsei University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2022-12-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.